{"pub": "axios", "url": "https://axios.com/drug-prices-unsupported-icer-report-238d9ad4-23c4-4b68-9fac-b24fc74ef4ec.html", "downloaded_at": "2019-10-09 00:26:30.081133+00:00", "title": "Drug price hikes for big medicines are \"unsupported,\" report says", "language": "en", "text": "By the numbers: Here are the drugs (and manufacturers) highlighted in ICER's report, along with the increase in net spending attributable to each drug's price increase.\n\nHumira (AbbVie): $1.9 billion\n\nRituxan (Roche): $806 million\n\nLyrica (Pfizer): $688 million\n\nTruvada (Gilead Sciences): $550 million\n\nNeulasta (Amgen): $489 million\n\nCialis (Eli Lilly): $403 million\n\nTecfidera (Biogen): $313 million\n\nThose figures aren't just the dollars Americans spent on drug copays and other out-of-pocket costs. They mostly reflect the higher amounts people paid through health insurance premiums and taxes.\n\nA common thread: Most of those drugs have faced competition from generics or biosimilars. Erin Fox, a pharmacotherapy professor at the University of Utah, said in a tweet that is \"a typical time to jack up prices without adding value.\"\n\nThe other side: ICER published an appendix in the report, which has been in the works for months, that included rebuttals from the pharmaceutical firms in question.", "description": "Drug companies raised prices because they had patent power.", "authors": [], "top_image": "https://images.axios.com/vrLwpgTfWXcPyYS2SXTDpXAl3KQ=/0x0:4928x2772/1920x1080/2019/10/08/1570549882000.jpg", "published_at": "2019-10-08"}